Program
perfluorohexyloctane
Also written as “NOV03”, “Miebo” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.
Its studies are mostly in Dry Eye Syndromes, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 101 open or running | phase 4since Jan 19, 2023 | Oct 23, 2019 | none ahead |
| Novaliq | 10 open or running | phase 2since Nov 2, 2017 | Nov 2, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2017First study: phase 2 study in Dry Eye SyndromesNew to NovaliqNovaliq · NCT03333057 · 336 enrolled · United States
- Oct 23, 2019Bausch Health Companies's first studies: 2 phase 3 studies in Dry Eye SyndromesNew to Bausch Health CompaniesBausch Health Companies · NCT04140227, NCT04139798
- Sep 23, 2020Phase 3 study in Dry Eye SyndromesBausch Health Companies · NCT04567329 · 620 enrolled · United States
- Jan 19, 2023Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT05723770 · 33 enrolled · United States
- Mar 7, 20242 phase 4 studies in Dry Eye SyndromesBausch Health Companies · NCT06309953, NCT06346340
- Aug 20, 2024Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT06565650 · 216 enrolled · United States
- Jun 27, 2025Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT07054606 · 104 enrolled · United States
- Aug 6, 2025Phase 2 study in Dry Eye SyndromesBausch Health Companies · NCT07128628 · 443 enrolled · United States
- Aug 6, 2025Phase 3 study in Dry Eye SyndromesBausch Health Companies · NCT07111013
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07128628Dry Eye Syndromes · United States | 2 | Completed | Bausch Health Companies | May 28, 2026 | 443 |
| NCT07111013Dry Eye Syndromes | 3 | Withdrawn | Bausch Health Companies | Apr 2027 | 0 |
| NCT07054606Dry Eye Syndromes · United States | 4 | Completed | Bausch Health Companies | Nov 3, 2025 | 104 |
| NCT06565650Dry Eye Syndromes · United States | 4 | Active, not recruiting | Bausch Health Companies | Nov 2025 | 216 |
| NCT06346340Dry Eye Syndromes · United States | 4 | Completed | Bausch Health Companies | Feb 24, 2025 | 97 |
| NCT06309953Dry Eye Syndromes · United States | 4 | Completed | Bausch Health Companies | Jun 17, 2024 | 99 |
| NCT05723770Dry Eye Syndromes · United States | 4 | Completed | Bausch Health Companies | Dec 23, 2023 | 33 |
| NCT04567329Dry Eye Syndromes · United States | 3 | Completed | Bausch Health Companies | Aug 30, 2021 | 620 |
| NCT04140227Dry Eye Syndromes · United States | 3 | Completed | Bausch Health Companies | Jan 5, 2022 | 256 |
| NCT04139798Dry Eye Syndromes · United States | 3 | Completed | Bausch Health Companies | Mar 12, 2021 | 599 |
| NCT03333057Dry Eye Syndromes · United States | 2 | Completed | Novaliq | May 18, 2018 | 336 |
How it is read
Names in the registry
- “NOV03”, 4 entries
- “Miebo”, 3 entries
- “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
- “Perfluorohexyloctane ophthalmic solution”, 1 entry
- “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry
Codes read as this program: NOV03.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.